Doximity, Inc. (NASDAQ:DOCS) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Doximity, Inc. (NASDAQ:DOCS) has received a consensus recommendation of "Hold" from 22 brokerage firms, with a price target averaging $69.37.
• Analysts have issued mixed ratings, with two sell ratings, nine holds, ten buys, and one strong buy, while recent reports from Evercore ISI and Robert W. Baird have upgraded their target prices to $81.00 and $80.00 respectively.
• In recent insider trading, Director Timothy S. Cabral sold 20,000 shares for $1.5 million, significantly decreasing his ownership in the company.

Doximity, Inc. (NASDAQ:DOCS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty-two ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $69.3684.

A number of research firms have recently weighed in on DOCS. Evercore ISI boosted their target price on Doximity from $75.00 to $81.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 8th. Robert W. Baird boosted their target price on Doximity from $75.00 to $80.00 and gave the stock an "outperform" rating in a research report on Thursday, September 11th. The Goldman Sachs Group set a $64.00 target price on Doximity and gave the stock a "sell" rating in a research report on Wednesday, October 1st. Needham & Company LLC boosted their target price on Doximity from $67.00 to $75.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Finally, Raymond James Financial set a $75.00 target price on Doximity in a research report on Wednesday, September 10th.

Doximity Stock Performance

Shares of DOCS opened at $66.33 on Thursday. The stock has a fifty day moving average price of $69.51 and a two-hundred day moving average price of $61.52. Doximity has a 52-week low of $40.87 and a 52-week high of $85.21. The company has a market cap of $12.42 billion, a price-to-earnings ratio of 66.33, a PEG ratio of 4.10 and a beta of 1.38.

Doximity (NASDAQ:DOCS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. Doximity had a return on equity of 21.75% and a net margin of 36.60%.During the same period in the prior year, the business posted $0.28 earnings per share. The company's quarterly revenue was up 15.2% on a year-over-year basis. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, research analysts predict that Doximity will post 0.99 EPS for the current fiscal year.

Insider Transactions at Doximity

In related news, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $75.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the director directly owned 3,221 shares of the company's stock, valued at $241,575. The trade was a 86.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Regina M. Benjamin sold 5,000 shares of Doximity stock in a transaction on Friday, October 10th. The stock was sold at an average price of $70.84, for a total value of $354,200.00. Following the sale, the director directly owned 19,839 shares of the company's stock, valued at approximately $1,405,394.76. This trade represents a 20.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,000 shares of company stock worth $2,635,880 over the last 90 days. 31.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Doximity

Several large investors have recently modified their holdings of DOCS. GAMMA Investing LLC increased its holdings in shares of Doximity by 62.3% in the first quarter. GAMMA Investing LLC now owns 2,816 shares of the company's stock worth $163,000 after acquiring an additional 1,081 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Doximity by 196.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,570 shares of the company's stock worth $787,000 after acquiring an additional 8,995 shares in the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Doximity by 7.0% in the first quarter. State of Alaska Department of Revenue now owns 15,640 shares of the company's stock worth $907,000 after acquiring an additional 1,030 shares in the last quarter. Lecap Asset Management Ltd. boosted its position in shares of Doximity by 9.2% during the first quarter. Lecap Asset Management Ltd. now owns 42,506 shares of the company's stock worth $2,467,000 after buying an additional 3,566 shares during the period. Finally, Spire Wealth Management boosted its position in shares of Doximity by 73.2% during the first quarter. Spire Wealth Management now owns 615 shares of the company's stock worth $36,000 after buying an additional 260 shares during the period. 87.19% of the stock is currently owned by institutional investors.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.